Telix Pharmaceuticals Limited (ASX:TLX)

$6.58

right-arrow Created with Sketch. -0.61 (-8.48%)
MCAP $2.049B
Last trade 15.24pm 25/01/2022 20mins delayed

Latest Announcements

24/01/2022TLXTelix Pharmaceuticals Limited
24/01/2022 Price SensitivePSTLXTelix Pharmaceuticals Limited
24/01/2022 Price SensitivePSTLXTelix Pharmaceuticals Limited
24/01/2022 Price SensitivePSTLXTelix Pharmaceuticals Limited
20/01/2022 Price SensitivePSTLXTelix Pharmaceuticals Limited
12,439
MCap
11/01/2022TLXTelix Pharmaceuticals Limited
21/12/2021TLXTelix Pharmaceuticals Limited
21/12/2021 Price SensitivePSTLXTelix Pharmaceuticals Limited

Company Overview

Telix Pharmaceuticals Limited is a radiopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) to treat cancer. In MTR therapy, radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The Company's lead products include TLX250/TLX250-CDx for diagnosis and treatment of renal (kidney) cancer; TLX591/TLX591-CDx for diagnosis and treatment of metastatic castrate-resistant prostate cancer and TLX101 for the treatment of glioblastoma (brain cancer).The Company's pipeline include development and commercialization of several clinical-stage products that address unmet medical needs in oncology and rare diseases.

TLX in the news

Telix Pharmaceuticals (TLX) announces successful $175 million institutional placement which it says…
Telix Pharmaceuticals (TLX) enters a trading halt while it plans an upcoming…
Telix Pharmaceuticals’ (TLX) first patient has been dosed with TLX250-CDx for non-muscle…
The US Food and Drug Administration approves Telix Pharmaceuticals (TLX) prostate cancer…

Search Previous Announcements